The role of specimen banking in risk assessment

The risk assessment process is described with a focus on the hazard identification and dose-response components. Many of the scientific questions and uncertainties associated with these components are discussed, and the role for biomarkers and specimen banking in supporting these activities are assessed. Under hazard identification, the use of biomarkers in defining and predicting a) biologically adverse events; b) the progression of those events towards disease; and c) the potential for reversibility are explored. Biomarker applications to address high-to-low dose extrapolation and interindividual variability are covered under dose-response assessment. Several potential applications for specimen banking are proposed.